Showing of a Substantial Case of Irreparable Harm to Losing Plaintiff Justifies Injunction Against Defendant During Appeal

Aug 18, 2014

Reading Time : 1 min

Following a bench trial, but before the court issued a judgment, the parties stipulated to a preliminary injunction barring the defendants from marketing or selling its generic drug product until the court issued its decision on the merits. The court ultimately issued a judgment of invalidity, and the plaintiff appealed to the Federal Circuit. Nevertheless, the plaintiff moved for an injunction until the appeal is resolved. Judge Catherine C. Blake in the District of Maryland granted this injunction last week pending plaintiff's appeal, on the condition that plaintiff post a $10 million bond and move to expedite its appeal. The plaintiff claimed that it has a strong likelihood of success on appeal because the district court erred in its application of the law with respect to motivations to combine the prior art and inherency. The court noted that, although it stands by its judgment, it recognizes that this case presents a close call. The plaintiff has not demonstrated a strong likelihood of success on appeal, but plaintiff made a showing of a substantial case. And because the balance of hardships tips strongly in plaintiff’s favor as well, the showing of a substantial case is sufficient to award an injunction.

Par Pharmaceutical, Inc. et al v. TWi Pharmaceuticals, Inc., 1­11­cv­02466 (MDD August 12, 2014, Order) (Blake, J.).

Share This Insight

Categories

Previous Entries

IP Newsflash

December 18, 2025

The Federal Circuit recently vacated a $20 million jury verdict in favor of a patentee and remanded with instructions to dismiss the case for lack of subject matter jurisdiction, finding that the patentee did not own the asserted patents at the time it filed suit and therefore lacked standing.

...

Read More

IP Newsflash

December 17, 2025

The Federal Circuit recently affirmed a Patent Trial and Appeal Board decision finding claims that had been subject to an ex parte reexamination unpatentable. As a threshold issue, the court held that IPR estoppel under 35 USC § 315(e)(1) does not apply to ongoing ex parte reexaminations. Accordingly, the Patent Office did not err in continuing the reexamination after issuing final written decisions in co-pending IPRs.

...

Read More

IP Newsflash

December 15, 2025

The District of Delaware recently denied a defendant’s motion to dismiss plaintiff’s demand for enhanced damages based on willful infringement pursuant to 35 U.S.C. § 284, explaining that neither a demand for damages under § 284 nor an accusation of willful infringement amount to a claim for relief that can be subject to dismissal under Rule 12(b)(6).

...

Read More

IP Newsflash

December 9, 2025

The Federal Circuit recently denied a petition for a writ of mandamus that challenged the PTO Director’s reliance on “settled expectations” to discretionarily deny two inter partes review (IPR) petitions. In so doing, the court explained that, while it was not deciding whether the Director’s use of “settled expectations” was correct, the petitioner’s arguments about what factors the Director may consider when deciding whether to institute an IPR or post-grant review (PGR) are not generally reviewable and did not provide sufficient basis for mandamus review here.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.